MEDICINOVA, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
MEDICINOVA, INC. (MNOV) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-08-14
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.46.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.01, a 23.38% increase year-over-year.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $3.25.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.64, a 6.88% increase from fiscal 2021.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.47, a 21.59% decline from fiscal 2020.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $3.15, a 22.22% decline from fiscal 2019.
- MEDICINOVA, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $4.05, a 24.62% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2022-12-31 | $2.64 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $2.64 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $2.64 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $2.47 10-K/A · filed 2023-03-28 | |||
| 2021-09-30 | $2.46 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $2.49 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $2.46 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $3.15 10-K · filed 2022-02-16 | |||
| 2020-09-30 | $3.07 10-Q · filed 2020-10-26 | |||
| 2020-06-30 | $3.05 10-Q · filed 2020-07-28 | |||
| 2019-12-31 | $4.05 10-K · filed 2021-02-19 | |||
| 2019-09-30 | $4.04 10-Q · filed 2019-10-24 | |||
| 2019-06-30 | $4.04 10-Q · filed 2019-07-25 | |||
| 2019-03-31 | $4.01 10-Q · filed 2019-04-25 | |||
| 2018-12-31 | $3.25 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $3.25 10-Q · filed 2018-10-25 | |||
| 2018-06-30 | $3.25 10-Q · filed 2018-07-23 | |||
| 2018-03-31 | $3.25 10-Q · filed 2018-04-25 | |||
| 2017-12-31 | $4.04 10-K · filed 2019-02-13 | |||
| 2017-09-30 | $3.31 10-Q · filed 2017-10-23 | |||
| 2016-12-31 | $4.81 10-K · filed 2019-02-13 | |||
| 2016-09-30 | $4.81 10-Q · filed 2016-10-25 | |||
| 2016-06-30 | $4.95 10-Q · filed 2016-07-26 | |||
| 2016-03-31 | $5.25 10-Q · filed 2016-04-27 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-14 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $2.57 10-K · filed 2017-02-14 | |||
| 2014-09-30 | $2.59 10-Q · filed 2014-11-13 | |||
| 2013-12-31 | $2.44 10-K · filed 2014-03-27 | |||
| 2013-09-30 | $2.44 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $2.44 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $2.46 10-Q · filed 2013-05-08 | |||
| 2012-12-31 | $2.30 10-K · filed 2013-03-28 | |||
| 2012-09-30 | $2.30 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $2.30 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |